AR029471A1 - Forma cristalina de la sal de disodio del acido n- [4- [2-(2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil]benzoil] -l-glutrmico-forma cristalina heptahidrato-; procedimiento de uso de dicha forma en la fabricacion de medicamentos para el tratamiento del cancer; formulaciones farmaceu - Google Patents
Forma cristalina de la sal de disodio del acido n- [4- [2-(2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil]benzoil] -l-glutrmico-forma cristalina heptahidrato-; procedimiento de uso de dicha forma en la fabricacion de medicamentos para el tratamiento del cancer; formulaciones farmaceuInfo
- Publication number
- AR029471A1 AR029471A1 ARP010100844A ARP010100844A AR029471A1 AR 029471 A1 AR029471 A1 AR 029471A1 AR P010100844 A ARP010100844 A AR P010100844A AR P010100844 A ARP010100844 A AR P010100844A AR 029471 A1 AR029471 A1 AR 029471A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- heptahydrate
- oxo
- cancer
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe y reivindica una forma cristalina de la sal de disodio del ácido N-[4-[2-(2-amino-4,7-dihidro-4-oxo-3-H-pirrolo(2,3-d]pirimidin-5-il)etil]benzoil]-L-glutamico forma cristalina heptahidrato-; procedimiento de uso de dicha forma en la fabricacion de medicamentos para el tratamiento del cáncer; comprenden dicha forma cristalina heptahidrato artículos de fabricacion que comprenden dicha forma cristalina y procedimiento para preparar la forma cristalina mencionada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18496400P | 2000-02-25 | 2000-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029471A1 true AR029471A1 (es) | 2003-07-02 |
Family
ID=22679017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100844A AR029471A1 (es) | 2000-02-25 | 2001-02-23 | Forma cristalina de la sal de disodio del acido n- [4- [2-(2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil]benzoil] -l-glutrmico-forma cristalina heptahidrato-; procedimiento de uso de dicha forma en la fabricacion de medicamentos para el tratamiento del cancer; formulaciones farmaceu |
Country Status (36)
Country | Link |
---|---|
US (1) | US7138521B2 (es) |
EP (1) | EP1259513B1 (es) |
JP (1) | JP4846158B2 (es) |
KR (1) | KR100744917B1 (es) |
CN (1) | CN1183135C (es) |
AR (1) | AR029471A1 (es) |
AT (1) | ATE249462T1 (es) |
AU (1) | AU777047B2 (es) |
BR (1) | BR0108604A (es) |
CA (1) | CA2400155C (es) |
CO (1) | CO5261585A1 (es) |
CZ (1) | CZ303772B6 (es) |
DE (1) | DE60100750T2 (es) |
DK (1) | DK1259513T3 (es) |
DZ (1) | DZ3283A1 (es) |
EA (1) | EA004684B1 (es) |
EG (1) | EG24073A (es) |
ES (1) | ES2206403T3 (es) |
HK (1) | HK1051856A1 (es) |
HR (1) | HRP20020701B1 (es) |
HU (1) | HU229704B1 (es) |
IL (2) | IL150480A0 (es) |
MX (1) | MXPA02008242A (es) |
MY (1) | MY124784A (es) |
NO (1) | NO323422B1 (es) |
NZ (1) | NZ519796A (es) |
PE (1) | PE20011082A1 (es) |
PL (1) | PL208061B1 (es) |
PT (1) | PT1259513E (es) |
SI (1) | SI1259513T1 (es) |
SK (1) | SK287375B6 (es) |
SV (1) | SV2002000321A (es) |
TW (1) | TWI237024B (es) |
UA (1) | UA72791C2 (es) |
WO (1) | WO2001062760A2 (es) |
ZA (1) | ZA200205265B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100364993C (zh) * | 2003-05-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 培美曲噻盐及其制备方法 |
CN100364994C (zh) * | 2004-11-25 | 2008-01-30 | 重庆医药工业研究院有限责任公司 | 培美曲塞二钠的一种新晶型及其制备方法 |
JP2009514889A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにsaha及びボルテゾミブを用いる方法 |
CA2622136A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and erlotinib for treating cancer |
US7994180B2 (en) * | 2006-08-14 | 2011-08-09 | Sicor Inc. | Processes for preparing intermediates of pemetrexed |
JP2008543975A (ja) * | 2006-08-14 | 2008-12-04 | シコール インコーポレイティド | 高度に純粋なペメトレキセド二酸およびその調製方法 |
US8088919B2 (en) * | 2006-08-14 | 2012-01-03 | Sicor Inc. | Crystalline forms of pemetrexed diacid and processes for the preparation thereof |
KR101083230B1 (ko) | 2006-08-14 | 2011-11-11 | 시코르, 인크. | 페메트렉세드 이산의 동결 건조된 약학적 허용염의 제조 방법 |
EP2086323A4 (en) * | 2006-11-03 | 2010-01-06 | Univ Maryland | METHOD OF USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA |
EP2129674A2 (en) * | 2007-04-03 | 2009-12-09 | Dr. Reddy's Laboratories Ltd. | Solid forms of pemetrexed |
CN101417998B (zh) | 2007-10-24 | 2012-10-24 | 重庆医药工业研究院有限责任公司 | 一种培美曲塞盐的纯化方法 |
EP2072518A1 (en) * | 2007-12-23 | 2009-06-24 | Sun Pharma Advanced Research Company Limited | Stable Amorphous Form of Pemextred Disodium |
EP2334685A4 (en) * | 2008-09-08 | 2011-10-26 | Reddys Lab Ltd Dr | AMORPHOUS PEMETREXED DISODIUM |
WO2010030598A2 (en) * | 2008-09-11 | 2010-03-18 | Dr. Reddy's Laboratories Limited | Pharmaceutical formulations comprising pemetrexed |
CN101684121B (zh) | 2008-09-22 | 2013-04-03 | 重庆医药工业研究院有限责任公司 | 培美曲塞二酸的新晶型及其制备方法 |
CN102050825B (zh) * | 2009-11-05 | 2014-12-17 | 上海创诺制药有限公司 | 制备培美曲塞二钠2.5水结晶的方法 |
US9174991B2 (en) | 2009-11-24 | 2015-11-03 | Azad Pharmaceutical Ingredients Ag | Crystalline form of pemetrexed disodium |
CN102372719B (zh) * | 2010-08-26 | 2013-10-30 | 齐鲁制药有限公司 | 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法 |
KR101069128B1 (ko) * | 2011-03-10 | 2011-09-30 | 건일제약 주식회사 | 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법 |
US9051322B2 (en) | 2011-03-23 | 2015-06-09 | Scinopharm Taiwan, Ltd. | Process for the production of a pemetrexed salt |
JP5826371B2 (ja) * | 2011-03-25 | 2015-12-02 | サイノファーム タイワン リミテッド | ペメトレキセド塩の製造方法 |
ITRM20120398A1 (it) | 2012-08-08 | 2014-02-09 | Berlin Chemie Ag | Procedimento di sintesi pemetrexed e suo sale di lisina. |
CN102911176B (zh) * | 2012-10-10 | 2015-07-22 | 德州德药制药有限公司 | 一种培美曲塞二钠的制备方法 |
WO2014060959A1 (en) * | 2012-10-17 | 2014-04-24 | Shilpa Medicare Limited | Crystalline pemetrexed dipotassium process |
EP2953616A2 (en) | 2013-02-06 | 2015-12-16 | Cipla House | Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes |
EP3308770A1 (en) | 2013-04-12 | 2018-04-18 | Actavis Group PTC EHF | Pemetrexed formulation |
KR101485243B1 (ko) | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
JP6094388B2 (ja) * | 2013-06-07 | 2017-03-15 | ニプロ株式会社 | ペメトレキセドを含む注射用組成物 |
JP6248189B2 (ja) | 2013-06-14 | 2017-12-13 | シントン・ベスローテン・フェンノートシャップ | 安定な抗がん剤のアルギニン塩とそれを含む組成物 |
WO2015008221A1 (en) | 2013-07-16 | 2015-01-22 | Dr. Reddy’S Laboratories Limited | Novel crystalline forms of pemetrexed tromethamine salts |
PL3040074T3 (pl) | 2013-10-03 | 2019-03-29 | Fujifilm Corporation | Preparat iniekcyjny i sposób jego wytwarzania |
NZ630292A (en) * | 2013-11-25 | 2015-02-27 | Shilpa Medicare Ltd | Process for crystalline pemetrexed dipotassium salt |
NZ630299A (en) | 2014-06-30 | 2014-11-28 | Shilpa Medicare Ltd | Pemetrexed dipotassium formulations |
CA2962383C (en) | 2014-10-30 | 2019-10-08 | Scinopharm Taiwan, Ltd. | Crystalline forms of pemetrexed diacid and manufacturing processes therefor |
CN105566328B (zh) * | 2014-11-06 | 2018-04-24 | 博瑞生物医药(苏州)股份有限公司 | 培美曲塞二酸多晶型的制备方法 |
CN109906071A (zh) * | 2017-10-10 | 2019-06-18 | 太阳制药工业公司 | 培美曲塞的静脉输注剂型 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO169490C (no) * | 1988-03-24 | 1992-07-01 | Takeda Chemical Industries Ltd | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater |
KR0162654B1 (ko) * | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
US5416211A (en) * | 1992-09-25 | 1995-05-16 | Eli Lilly And Company | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines |
AU4163197A (en) * | 1996-08-30 | 1998-03-19 | Eli Lilly And Company | Nonclassical pyrrolo{2,3-d}pyrimidine antifolates |
ZA987550B (en) * | 1997-09-26 | 2000-02-21 | Lilly Co Eli | Processes and intermediates useful to make antifolates. |
IL135190A (en) * | 1997-09-26 | 2005-03-20 | Lilly Co Eli | Processes and intermediates useful to make antifolates |
WO2001014379A2 (en) * | 1999-08-23 | 2001-03-01 | Eli Lilly And Company | A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor |
-
2001
- 2001-02-12 PT PT01906554T patent/PT1259513E/pt unknown
- 2001-02-12 EP EP01906554A patent/EP1259513B1/en not_active Expired - Lifetime
- 2001-02-12 PL PL356423A patent/PL208061B1/pl unknown
- 2001-02-12 BR BR0108604-9A patent/BR0108604A/pt not_active Application Discontinuation
- 2001-02-12 ES ES01906554T patent/ES2206403T3/es not_active Expired - Lifetime
- 2001-02-12 DZ DZ013283A patent/DZ3283A1/fr active
- 2001-02-12 DK DK01906554T patent/DK1259513T3/da active
- 2001-02-12 CA CA002400155A patent/CA2400155C/en not_active Expired - Fee Related
- 2001-02-12 KR KR1020027011122A patent/KR100744917B1/ko not_active IP Right Cessation
- 2001-02-12 CZ CZ20022875A patent/CZ303772B6/cs not_active IP Right Cessation
- 2001-02-12 NZ NZ519796A patent/NZ519796A/xx not_active IP Right Cessation
- 2001-02-12 MX MXPA02008242A patent/MXPA02008242A/es active IP Right Grant
- 2001-02-12 SK SK1186-2002A patent/SK287375B6/sk not_active IP Right Cessation
- 2001-02-12 DE DE60100750T patent/DE60100750T2/de not_active Expired - Lifetime
- 2001-02-12 AT AT01906554T patent/ATE249462T1/de active
- 2001-02-12 AU AU34451/01A patent/AU777047B2/en not_active Ceased
- 2001-02-12 JP JP2001562542A patent/JP4846158B2/ja not_active Expired - Fee Related
- 2001-02-12 CN CNB01805627XA patent/CN1183135C/zh not_active Expired - Fee Related
- 2001-02-12 IL IL15048001A patent/IL150480A0/xx active IP Right Grant
- 2001-02-12 EA EA200200905A patent/EA004684B1/ru not_active IP Right Cessation
- 2001-02-12 HU HU0204232A patent/HU229704B1/hu unknown
- 2001-02-12 SI SI200130032T patent/SI1259513T1/xx unknown
- 2001-02-12 US US10/182,991 patent/US7138521B2/en not_active Expired - Lifetime
- 2001-02-12 WO PCT/US2001/001229 patent/WO2001062760A2/en active IP Right Grant
- 2001-02-21 EG EG20010167A patent/EG24073A/xx active
- 2001-02-23 TW TW090104119A patent/TWI237024B/zh not_active IP Right Cessation
- 2001-02-23 AR ARP010100844A patent/AR029471A1/es unknown
- 2001-02-23 SV SV2001000321A patent/SV2002000321A/es unknown
- 2001-02-23 CO CO01014634A patent/CO5261585A1/es not_active Application Discontinuation
- 2001-02-23 PE PE2001000194A patent/PE20011082A1/es not_active Application Discontinuation
- 2001-02-23 MY MYPI20010823A patent/MY124784A/en unknown
- 2001-12-02 UA UA2002086886A patent/UA72791C2/uk unknown
-
2002
- 2002-06-27 IL IL150480A patent/IL150480A/en not_active IP Right Cessation
- 2002-07-01 ZA ZA200205265A patent/ZA200205265B/xx unknown
- 2002-08-21 NO NO20023974A patent/NO323422B1/no not_active IP Right Cessation
- 2002-08-26 HR HR20020701A patent/HRP20020701B1/xx not_active IP Right Cessation
-
2003
- 2003-04-09 HK HK03102573A patent/HK1051856A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR029471A1 (es) | Forma cristalina de la sal de disodio del acido n- [4- [2-(2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil]benzoil] -l-glutrmico-forma cristalina heptahidrato-; procedimiento de uso de dicha forma en la fabricacion de medicamentos para el tratamiento del cancer; formulaciones farmaceu | |
GEP20053511B (en) | ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase | |
NO20035210D0 (no) | 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer | |
BG111017A (bg) | Нови кристални и аморфна форми на съединението триазоло (4, 5- d)пиримидин | |
AR064722A2 (es) | Procesos para preparar formulaciones farmaceuticas de agentes antineoplasicos, polvo liofilizado, articulo que lo comprende y formulacion farmaceutica | |
PT793498E (pt) | Compostos heterociclicos biciclicos para o tratamento da impotencia | |
CO5680109A1 (es) | Compuestos para el tratamiento de la disfuncion sexual femenina | |
ECSP056246A (es) | DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA | |
BR0209774A (pt) | Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento | |
BR0315988A (pt) | Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos | |
AR004108A1 (es) | Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas | |
AR029312A1 (es) | Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh, procesos para su produccion, formulacion farmaceutica, y uso de estos compuestos para la elaboracion de un medicamento. | |
BR0209283A (pt) | Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme | |
UY26371A1 (es) | Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen | |
ECSP055642A (es) | Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas | |
DE69302829T2 (de) | Bicyclische pyrimidinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate | |
AR035553A1 (es) | Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos. | |
PA8519501A1 (es) | Farnesil transferasa inhibidora del enantiomero de quinolina 1,2-anillado | |
ES2072386T3 (es) | Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b. | |
AR027624A1 (es) | Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos | |
ES2151922T3 (es) | Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero. | |
MXPA05012772A (es) | Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina. | |
AR032695A1 (es) | Composicion farmaceutica | |
ECSP003631A (es) | Nueva forma cristalina de la sal disodica del acido n-[4-[2-amino-4,7 - dihidro-4-oxo-3h-pirrolo [2,3-d]-pirimidin-5-il)etil] benzoil]-l-glutamico y procedimientos para el mismo | |
PT1005471E (pt) | Pirazolo¬3,4-d|pirimidinas com accao anticonvulsivas e antialergica/antiasmatica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |